These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37772709)

  • 1. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.
    Farmaki E; Nath A; Emond R; Karimi KL; Grolmusz VK; Cosgrove PA; Bild AH
    Elife; 2023 Sep; 12():. PubMed ID: 37772709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
    Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
    Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma.
    Pruss M; Dwucet A; Tanriover M; Hlavac M; Kast RE; Debatin KM; Wirtz CR; Halatsch ME; Siegelin MD; Westhoff MA; Karpel-Massler G
    Br J Cancer; 2020 Apr; 122(8):1146-1157. PubMed ID: 32115576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
    Hurvitz SA; Kalous O; Conklin D; Desai AJ; Dering J; Anderson L; O'Brien NA; Kolarova T; Finn RS; Linnartz R; Chen D; Slamon DJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):669-80. PubMed ID: 25663547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
    BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM
    Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
    Chen L; Yang G; Dong H
    Med Sci Monit; 2019 Jan; 25():77-86. PubMed ID: 30605443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Drago JZ; Formisano L; Juric D; Niemierko A; Servetto A; Wander SA; Spring LM; Vidula N; Younger J; Peppercorn J; Yuen M; Malvarosa G; Sgroi D; Isakoff SJ; Moy B; Ellisen LW; Iafrate AJ; Arteaga CL; Bardia A
    Clin Cancer Res; 2019 Nov; 25(21):6443-6451. PubMed ID: 31371343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Petrossian K; Nguyen D; Lo C; Kanaya N; Somlo G; Cui YX; Huang CS; Chen S
    Breast Cancer Res Treat; 2018 Aug; 170(3):499-506. PubMed ID: 29623577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.